BioSpace News Archive

LEO Pharma A/S announces today that it has enrolled the first patients in two new phase 2b clinical studies to investigate delgocitinib, a novel topical pan-Janus kinase inhibitor (JAKi), as a monotherapy for adults with mild-to-severe atopic dermatitis (AD) as well as mild-to-severe chronic hand eczema (CHE).

Prestigious accolade recognises the potential impact of the Company’s disruptive exosome drug platform

Single dose, proprietary, rimegepant Zydis ODT formulation provided rapid onset of pain relief with numerical separation from placebo as early as 15 minutes and statistically significant by 60 minutes

CRH Medical Corporation announces that it has completed an accretive transaction whereby the Company has acquired a gastroenterology (“GI”) anesthesia practice in Tennessee.

New portfolio of services expands on the bank’s expertise in serving the financial needs of Health Care Practitioners

Sunny Pharmtech, Inc. and Vitruvius Therapeutics Inc. announced today that their Abbreviated New Drug Application (“ANDA”) for Aminocaproic Acid Tablets 500 mg and 1000 mg tablets has received final approval from the U.S. Food and Drug Administration.

Sesen Bio, Inc. today announced the appointment of Dennis Kim, M.D., MPH, as chief medical officer.

Genesis Innovation Group’s cultivate(MD) Capital Fund II, LP, a fund focused on investments in early stage healthcare companies with innovative technologies, announces its investment into SpinTech.

Merck announced today that Robert M. Davis, chief financial offer and executive vice president, Merck Global Services, is scheduled to present at Citi’s 2018 Global Healthcare Conference in New York on Dec. 5, 2018 at 8:45 a.m. EST.

Customizable Skin Treatments Address Patient-Specific Concerns